Further investigations showed that PI3K/Akt pathway was involved in lncARSR-related doxorubicin resistance in HCC, as inhibition of PI3K/Akt pathway reversed lncARSR overexpression-induced doxorubicin resistance 140. This evidence concerns the gene LNCARSR and hepatocellular carcinoma.